Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

In silico modeling of p450 substrates, inhibitors, activators, and inducers.

DeLisle RK, Otten J, Rhodes S.

Comb Chem High Throughput Screen. 2011 Jun 1;14(5):396-416. Review.

PMID:
21470185
2.

The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting.

O'Donnell CJ, Grime K, Courtney P, Slee D, Riley RJ.

Drug Metab Dispos. 2007 Mar;35(3):381-5. Epub 2006 Dec 1.

3.

Molecular modeling of human cytochrome P450-substrate interactions.

Lewis DF.

Drug Metab Rev. 2002 Feb-May;34(1-2):55-67. Review.

PMID:
11996012
5.
6.

Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism.

Lewis DF, Modi S, Dickins M.

Drug Metabol Drug Interact. 2001;18(3-4):221-42. Review.

PMID:
11791886
7.

Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.

Lee KS, Kim SK.

J Appl Toxicol. 2013 Feb;33(2):100-8. doi: 10.1002/jat.1720. Epub 2011 Sep 14.

PMID:
21915887
8.

Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.

Temesvári M, Kóbori L, Paulik J, Sárváry E, Belic A, Monostory K.

J Pharmacol Exp Ther. 2012 Apr;341(1):294-305. doi: 10.1124/jpet.111.189597. Epub 2012 Jan 19.

9.

Structure-activity relationship for human cytochrome P450 substrates and inhibitors.

Lewis DF, Modi S, Dickins M.

Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. Review.

PMID:
11996013
10.

Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine.

Fang J, Coutts RT, McKenna KF, Baker GB.

Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.

PMID:
9840430
11.

Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Maréchal JD, Kemp CA, Roberts GC, Paine MJ, Wolf CR, Sutcliffe MJ.

Br J Pharmacol. 2008 Mar;153 Suppl 1:S82-9. Epub 2007 Nov 19. Review.

12.

Modelling cytochromes P450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity.

Carosati E.

Drug Discov Today Technol. 2013 Spring;10(1):e167-75. doi: 10.1016/j.ddtec.2012.09.007. Review.

PMID:
24050246
13.
15.

Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation.

VandenBrink BM, Davis JA, Pearson JT, Foti RS, Wienkers LC, Rock DA.

Mol Pharmacol. 2012 Nov;82(5):835-42. doi: 10.1124/mol.112.080739. Epub 2012 Aug 2.

16.

Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.

Korolev D, Balakin KV, Nikolsky Y, Kirillov E, Ivanenkov YA, Savchuk NP, Ivashchenko AA, Nikolskaya T.

J Med Chem. 2003 Aug 14;46(17):3631-43.

PMID:
12904067
17.

HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.

Kanebratt KP, Andersson TB.

Drug Metab Dispos. 2008 Jan;36(1):137-45. Epub 2007 Oct 22.

18.

Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.

Arbus C, Benyamina A, Llorca PM, Baylé F, Bromet N, Massiere F, Garay RP, Hameg A.

Eur J Pharm Sci. 2007 Dec;32(4-5):357-66. Epub 2007 Sep 14.

PMID:
17951033
19.
20.

Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities.

Niwa T, Murayama N, Yamazaki H.

Curr Drug Metab. 2011 Jul;12(6):549-69. Review.

PMID:
21476971
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk